Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.

Abstract: A method of preparing siRNAs for selective inhibition of target mRNA isotypes comprises: dividing target mRNA isotypes intended to inhibit the expression thereof and non-target mRNA isotypes from the mRNA isotypes of a gene; allotting a common location information region (A) of exons on genome DNA corresponding to the target mRNA isotypes; allotting a location information region (B) present specifically in exons of genome DNA corresponding to target mRNAs by excluding the location information region of exons on genome DNA corresponding to non-target mRNA from the location information region (A); determining base sequences in the target mRNAs corresponding to the location information region (B); and obtaining siRNA sequences for inhibiting the determined base sequences specifically.

Abstract: A inhibition method of target mRNA expression includes: (a) obtaining binding energy of a double combination section on a dsRNA sequence of all combination comprising complementary nucleotides to a random target mRNA; (b) dividing the binding energy into four sections on the dsRNA sequence of each combination to obtain a difference of the mean binding energy between each section and convert into a score of a relative combination energy pattern; (c) selecting siRNA whose inhibition efficiency to target mRNA is expected to be high by applying the converted score to the dsRNA sequence with other factors that affect the efficiency of siRNA; and (d) inhibiting target mRNA expression using the selected siRNA.

Abstract: The present invention relates to a dried oligonucleotide composition and a method for producing the same. More specifically, it relates to a dried oligonucleotide composition produced by the steps comprising adding a substance for preventing the oligonucleotide from being separated and lost, which is adhesive to a storage container containing the oligonucleotide composition, in order to prevent the oligonucleotide from being separated and lost during manufacturing and distributing the dried oligonucleotide composition, optionally adding a non-reactive dye substance, and drying the resulting solution. The dried oligonucleotide composition of the present invention can be prevented from being separated and lost during manufacturing step, or transporting step after packaging, and the presence or absence of the oligonucleotide in the storage container can be easily confirmed with naked eyes.

Abstract: The present invention relates a process of quality examining for microarray of biological material. More particularly, the present invention is directed to a process of quality examining for microarray of biological material, which comprises 1) a step for mixing probe and a compound which emits light or heat and does not react with said probe, 2) a step for microarraying the mixture obtained in step 1) on a substrate, and 3) a step for measuring light or heat emitted by the scanning of each spots of the microarray mixture.

Abstract: The present invention is related to hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for delivering the siRNA in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.

Abstract: The present invention relates to microorganisms for preventing or treating obesity or diabetes mellitus which have excellent viability and produce polysaccharides efficiently in the intestines. More particularly, is directed to microorganisms for preventing or treating obesity or diabetes mellitus, which are capable of reducing the amount of monosaccharides or disaccharides that can be absorbed into the intestine by converting those mono or disaccharides into polymeric materials that cannot be absorbed in the intestines. The present invention is also directed to a pharmaceutical composition containing pharmaceutically effective amount of the microorganisms and a food composition containing the microorganisms as an active ingredient. Preferred microorganisms are Lactobacillus reuteri KCTC-10301BP and Lactobacillus fermentum KCTC-10458BP.

Abstract: The present invention relates to a process for amplifying DNA of an organism. More particularly, the present invention is directed to a process for amplifying DNA of an organism through Polymerase Chain Reaction(PCR) without any information regarding a primer needed for amplifying DNA of an organism.

Abstract: The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms. Preferred microorganisms are Lactobacillus sp. BC-Y009 and Acetobacter sp. BC-Y058.

Abstract: A method for obtaining DNA from fish spermatogonia comprises (i) disrupting fish spermatogonium to obtain a milky-white colloid, (ii) adding an alkaline solution of pH 8 to pH 12, containing more than 1 mol of salts, such as monovalent salts, to the milky-white colloid, to separate DNA from protamines, and then (iii) adding ethanol solution to the resultant mixture, effecting a precipitation of DNA.

Abstract: The present invention relates to a bio-molecular microchip and manufacturing process thereof. More particularly, the present invention is directed to a bio-molecular microchip comprising a substrate; and an amine group-containing bio-molecule immobilized onto a glycidyl moiety-containing polyacrylamide gel via covalent bonds formed between the glycidyl moiety of the polyacryl amide gel and the amine group of the bio-molecule by epoxy ring-opening reaction.

Abstract: The present invention relates to a process for the preparation of full-length complementary DNA (cDNA).

Abstract: The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

Abstract: The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

Abstract: A method and apparatus for sterilizing and disinfecting bedclothes. The method includes preparing a sterilizing room defined by a cover; placing bedclothes into the sterilizing room; and exposing the bedclothes to ultraviolet rays and ozone generated by a generator in communication with the sterilizing room. The apparatus includes a generator for generating ultraviolet rays and ozone and a cover for defining a sterilizing room to accommodate the bedclothes.

Abstract: The present invention relates to a process for the preparation of full-length complementary DNA (cDNA).

Abstract: The present invention relates to a process for the preparation of full-length complementary DNA (cDNA).

Abstract: The present invention relates to an apparatus for automatic measuring of water toxicity. More specifically, the present invention provides an apparatus for automatic and continuous measuring of water toxicity and/or contamination using luminescent microorganisms living in freshwater.

Abstract: A method for obtaining DNA from fish spermatogonia comprises (i) disrupting fish spermatogonium to obtain a milky-white colloid, (ii) adding an alkaline solution of pH 8 to pH 12, containing more than 1 mol of salts, such as monovalent salts, to the milky-white colloid, to separate DNA from protamines, and then (iii) adding ethanol solution to the resultant mixture, effecting a precipitation of DNA.

Abstract: The present invention relates to a method for detecting and identifying mycobacterial species which comprises steps of amplifying 342 bp of rpoB gene fragments from clinically isolated mycobacterial using mycobacterial rpoB-specific PCR primers; sequencing 306 bp regions of the amplified 342 bp of rpoB gene fragments except the primer regions; and, inferring a phylogenetic tree with reference species. In accordance with the present invention, it was found that rpoB sequences from 44 mycobacterial species provide a basis for systematic phylogenetic relationship which can be used to identify clinically isolated mycobacteria that are pathogenic or potentially so. Accordingly, the amplification of rpoB DNA followed by automated sequencing and the analysis of phylogenetic relationships with the reference species can be used efficiently to detect and identify clinical isolates of mycobacteria which have not been identified by the conventional methods.